NAFLD study group Committee
Chair: Amalia Gastaldelli
Board members: Gianluca Svegliati-Baroni, Kenneth Cusi, Hannele Yki-Järvinen, Leanne Hodson, Stefano Romeo, Michael Trauner, Giulio Marchesini
Organizing Committee: Stefano Romeo, Rosellina Margherita Mancina, Piero Pingitore

PROGRAM

MONDAY 8th May 2017

10:30-11:00 REGISTRATION
11:00-11:10 OPENING WORDS: Stefano Romeo

11:10-12:15 SESSION 1 – GUT-LIVER AXIS
11:10-12:00 Fredrik Bäckhed
Sweden
The role of gut microbiota in the susceptibility to metabolic diseases
12:00-12:15 Irene Pierantonelli
Italy
The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3-inflammasome

12:15-13:00 LUNCH

13:10-15:00 SESSION 2 – LIVER DISEASE AND DIABETES MELLITUS 2
Moderator: Hannele Yki-Järvinen

13:10-14:00 Stefan Norbert
Germany
Interplay between type 2 diabetes and NAFLD
14:00-14:15 Paul Afolabi
United Kingdom
The relationship between hepatic mitochondrial function and type 2 diabetes in patients with NAFLD
14:15-14:30 Christopher Byrne
United Kingdom
Non-alcoholic fatty liver disease-related mortality in type 2 diabetes
14:30-14:45 Karl Björkström
Sweden
Histological scores for fat and fibrosis predicts development of type 2 diabetes in NAFLD
14:45-14:50 Roy Taylor
United Kingdom
Degree of non-alcoholic fatty liver disease is the greatest metabolic abnormality in early type 2 diabetes
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Country</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:50-14:55</td>
<td>Diego Olschowsky Borges</td>
<td>Portugal</td>
<td>Genetic or dietary derived insulin clearance impairment: the major drivers of glucose intolerance</td>
</tr>
<tr>
<td>14:55-15:00</td>
<td>Fátima Martins</td>
<td>Portugal</td>
<td>Nitric oxide governs insulin bioavailability through controlling insulin clearance in a model of sucrose-induced hepatic lipogenesis</td>
</tr>
<tr>
<td>15:00-16:10</td>
<td>SESSION 3 – MISCELLANEA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Jussi Pihlajamäki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Fabio Marra</td>
<td>Italy</td>
<td>Cross-talk between the IDO-kynurenine pathway al IL-1 beta in experimental NASH</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>Kelly Bowden Davies</td>
<td>United Kingdom</td>
<td>The metabolic consequences of short-term increased sedentary behaviour</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Henry Wilman</td>
<td>United Kingdom</td>
<td>Characterisation of liver fat in the UK Biobank cohort</td>
</tr>
<tr>
<td>15:45-15:50</td>
<td>Nádia Duarte</td>
<td>Portugal</td>
<td>Severe Shifts in Kupffer Cell Populations Are Mirrored by Dipeptidyl Peptidase-4 (DPP-4/CD26) Activity in the Serum</td>
</tr>
<tr>
<td>15:50-15:55</td>
<td>Andriana Kaliora</td>
<td>Greece</td>
<td>The MAST4HEALTH Consortium</td>
</tr>
<tr>
<td>15:55-16:00</td>
<td>Metin Basaranoglu</td>
<td>Turkey</td>
<td>Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list</td>
</tr>
<tr>
<td>16:00-16:05</td>
<td>Maria João Meneses</td>
<td>Portugal</td>
<td>Mesenchymal Stromal Cells from the Umbilical Cord (UCX®) protect against diet-induced obesity</td>
</tr>
<tr>
<td>16:10-16:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-18:35</td>
<td>SESSION 4 – DIAGNOSIS AND TREATMENT OF NAFLD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Stefano Romeo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-17:30</td>
<td>one on one session</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Luca Valenti</td>
<td>Italy</td>
<td>Liver biopsy why and when?</td>
</tr>
<tr>
<td></td>
<td>Banerjee Rajarshi</td>
<td>United Kingdom</td>
<td>Non-invasive diagnosis instead of liver biopsy?</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>Sanne Skovgaard Veidal</td>
<td>Denmark</td>
<td>Liraglutide, elafibraron and obeticholic acid show different efficacy profiles in diet-induced and genetically obese mouse models with biopsy-confirmed NASH</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>Henry Wilman</td>
<td>United Kingdom</td>
<td>Non-invasive multiparametric MRI (LiverMultiScan™) effectively excludes NASH and liver fibrosis in at risk patients</td>
</tr>
<tr>
<td>18:00-18:15</td>
<td>Amalia Gastaldelli</td>
<td>Italy</td>
<td>Effect of Dietary Intervention or Pioglitazone Therapy on Hepatic and Visceral Fat, Insulin Resistance and Liver Histology in Patients with NASH</td>
</tr>
<tr>
<td>Time</td>
<td>Presenter</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 18:15-18:20  | Kelly Bowden Davies  
United Kingdom | Habitual physical activity, independent of moderate-vigorous activity, predicts amount of liver fat and metabolic health status |
| 18:20-18:25  | Mukul Jain  
India            | Saroglitazar magnesium in non-alcoholic steatohepatitis? A case for further clinical investigation |
| 18:25-18:30  | Rocio Gallego-Durán  
Spain          | Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease |
| 18:30-18:35  | Mostafa Elkady  
Egypt          | `A case report`: A Dramatic Response to Albendazole in a Case of a Large Hepatic focal lesion Mimicking Hepatocellular carcinoma` |

18:45-20:45  DINNER  
21:00  BUS TRANSFER TO GOTHIA TOWERS
TUESDAY 9th May 2017

07:50  BUS TRANSFER FROM GOTHIA TOWERS
08:30  Speakers upload the talks for the day

09:00-10:40  SESSION 5 – GENETICS AND MOLECULAR MECHANISMS OF NAFLD
Moderator: Amalia Gastaldelli

09:05-10:00  Stefano Romeo
Sweden  Can we use genetics of NAFLD in clinical trials or practice?
10:00-10:15  Piero Pingitore
Sweden  Recombinant MBOAT7 protein shows acyltransferase activity primarily transferring arachidonic acid (aa) from arachidonoyl-coa to lysophosphatidylinositol
10:15-10:30  Martijn Brouwers
Netherlands  PNPLA3, TM6SF2 and MBOAT7 genotypes and coronary artery disease
10:30-10:45  Ville Männistö
Finland  Liver phosphatidylcholine content decrease in NASH is not explained by PEMT rs7946 genotype
10:45-11:00  Paula Walle
Finland  Altered methylation of FADS2 in NASH is partly explained by FADS2 genotypes

11:00-11:10  COFFEE BREAK

11:10-13:00  SESSION 6 – DIET, DISLYPIDEMIA, LIPOTOXICITY IN NAFLD
Moderator: Luca Valenti

11:10-12:00  Christopher Byrne
United Kingdom  Dietary risk factors and interventions in NAFLD
12:00-12:15  Lars Johansson
Sweden  Integrated assessment of body composition, liver lipids and liver volume using MRI. Experience from over 20 clinical trials including diet, surgery, and pharmacological interventions.
12:15-12:30  Panu Luukkonen
Finland  Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD
12:30-12:45  Fredrik Rosqvist
Sweden  Plasma ceramides are modified by dietary fat quality and are related to liver fat accumulation and lipogenic markers during overfeeding
12:45-12:50  John Jones
Portugal  Differential fractional synthetic and elongation rates of hepatic saturated fatty acids and oleate from [U-13C]glucose presented alongside unlabeled fructose in healthy mice

13:00-14:00  WORKING LUNCH FOR COLLABORATIVE INITIATIVES
The meeting is kindly sponsored by Astra-Zeneca and University of Gothenburg